A two-site, two-arm, 34-week, double-blind, parallel-group, randomized controlled trial of reduced nicotine cigarettes in smokers with mood and/or anxiety disorders: trial design and protocol.

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

TRN: NCT01928758, registered August 21, 2013.

Who Took Part

By PubMed's age tags, the people studied were young adults and adults, both men and women.

Participants must have not had a quit attempt in the prior month, nor be planning to quit in the next 6 months, meet criteria for a current or lifetime unipolar mood and/or anxiety disorder based on the structured Mini-International Neuropsychiatric Interview, and must not have an unstable medical or psychiatric condition.

At the end of the randomization phase, participants will be offered the choice to either (a) quit smoking with assistance, (b) continue smoking free research cigarettes, or (c) return to purchasing their own cigarettes, for the final 12 weeks of the study.

How the Study Was Run

In design terms this was a randomized, double-blind and parallel-group study.

The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Therapeutic nicotine (patch, non-peptide), so expectations could not easily colour the readings.

The Therapeutic nicotine (patch, non-peptide) group and the comparison group ran side by side rather than switching.

The primary outcome measure is blood cotinine; key secondary outcomes are: exhaled carbon monoxide, urinary total NNAL- 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and 1-hydroxypyrene, oxidative stress biomarkers including 8-isoprostanes, measures of psychiatric symptoms (e.g., depression, anxiety), smoking behavior and dependence (e.g., cigarette consumption, quit attempts), and health effects (e.g., blood pressure, respiratory symptoms).

What Was Measured

PubMed files the paper under topics including Anxiety Disorders, Biomarkers, Carbon Monoxide, Clinical Protocols, Cotinine, Massachusetts and Mood Disorders.

The authors tagged it with the keywords Cigarettes, NNAL, RCT, Spectrum and Tobacco.

What This Means in Plain Language

The paper is a randomized, double-blind and parallel-group study of Therapeutic nicotine (patch, non-peptide).

Its findings take up roughly 1 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2017 (BMC public health), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.